Linezolide Kabi

Linezolid, the active ingredient in Linezolide Kabi, is an oxazolidinone antibiotic presented as an injection for intravenous use. It treats complicated skin and soft tissue infections, community‑acquired bacterial pneumonia, nosocomial pneumonia and infections caused by methicillin‑resistant Staphylococcus aureus (MRSA) in adult patients.

GNH USA supplies Linezolide Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linezolid is an oxazolidinone antibiotic used to treat serious bacterial infections affecting the skin, lungs and resistant organisms.

- Complicated skin and soft tissue infections: effective against Gram‑positive pathogens, including MRSA, reducing infection severity. - Community‑acquired bacterial pneumonia: improves clinical outcomes by eradicating susceptible Streptococcus pneumoniae and other typical agents. - Nosocomial pneumonia (including MRSA): provides intravenous therapy for hospital‑acquired lung infections resistant to other agents.

Linezolid may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, often self‑limiting. - Headache: transient cranial discomfort. - Thrombocytopenia: mild reduction in platelet count.

Serious or Rare Side Effects: - Myelosuppression: significant decrease in blood cell production, requiring monitoring. - Peripheral neuropathy: sensory changes that may become irreversible with prolonged use. - Lactic acidosis: rare metabolic disturbance presenting with rapid breathing and abdominal pain.

When prescribing Linezolid, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: adjust monitoring as accumulation may occur. - Hepatic dysfunction: evaluate liver function before and during therapy. - Concomitant serotonergic agents: avoid due to risk of serotonin syndrome. - Prolonged therapy (>14 days): monitor blood counts for myelosuppression. - Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Linezolid can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs), SNRIs, MAO inhibitors: risk of serotonin syndrome. - Tyramine‑containing foods and sympathomimetics: may cause hypertensive crisis. - Rifampin: reduces linezolid plasma concentrations, decreasing effectiveness.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Ethanol: potential disulfiram‑like reaction, advise caution. - NSAIDs: increased risk of bleeding when combined with anticoagulants.